Trevi Therapeutics Inc

NASDAQ:TRVI   1:34:39 PM EDT
0.61
-0.05 (-7.65%)
Products, Regulatory

Trevi Therapeutics Announces Clinical Trial Updates For Lead Indications

Published: 01/05/2022 19:00 GMT
Trevi Therapeutics Inc (TRVI) - Trevi Therapeutics Announces Clinical Trial Updates for Lead Indications.
Trevi Therapeutics Inc - Phase 2 Canal (chronic Cough in Ipf) Planned Interim Statistical Update 1q 2022, With Top-line Data 1h 2022.
Trevi Therapeutics Inc - Phase 2b/3 Prism (chronic Pruritus in Pn) Enrollment to End January 31, 2022, With Top-line Data 1h 2022.